Safety and efficacy of biologic therapies in psoriatic patientswith alcoholic cirrhosis: a French retrospective study of 23 cases

Abstract

There are few studies specifically addressing the safety and efficacy of biologic treatments, especially anti TNF-alpha agents, in psoriatic patients with cirrhosis as such patients are usually excluded from prospective interventional studies. However, one should be aware that biologics are often prescribed in this particular population for several reasons. This is probably due to the fact that physicians are usually reluctant to prescribe conventional systemic treatment such as methotrexate or acitretine in psoriatic patients with liver abnormalities because of their liver toxicity. In addition, there is a general agreement that biologics have very few pharmacologic interaction with liver function and are not contraindicated in case of liver insufficiency.

This article is protected by copyright. All rights reserved.